Ginkgo Bioworks Holdings (DNA) Operating Income Growth (3y) (2023 - 2026)
Ginkgo Bioworks Holdings (DNA) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 55.96% |
| 10 | Ginkgo Bioworks Holdings | 441.37 Mn | 297.50 Mn | 16.38 Mn | 30.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.84% |
| Dec 31, 2025 | 32.58% |
| Sep 30, 2025 | 48.39% |
| Jun 30, 2025 | 53.40% |
| Mar 31, 2025 | 50.69% |
| Dec 31, 2024 | 60.53% |
| Sep 30, 2024 | -27.44% |
| Jun 30, 2024 | -54.93% |
| Mar 31, 2024 | -46.07% |
| Dec 31, 2023 | -47.16% |
| Sep 30, 2023 | -102.65% |